Quest Diagnostics Incorporated (DGX) |
| 242.76 -1.85 (-0.76%) 08-28 16:00 |
| Open: | 245.17 |
| High: | 245.28 |
| Low: | 242.27 |
| Volume: | 639,931 |
| Market Cap: | 26,794(M) |
| PE Ratio: | 23.94 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 288.72 |
| Resistance 1: | 247.19 |
| Pivot price: | 240.22 |
| Support 1: | 233.46 |
| Support 2: | 224.97 |
| 52w High: | 247.19 |
| 52w Low: | 171.18 |
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
| EPS | 9.410 |
| Book Value | 68.330 |
| PEG Ratio | 2.04 |
| Gross Profit | 34.792 |
| Profit Margin (%) | 9.19 |
| Operating Margin (%) | 15.25 |
| Return on Assets (ttm) | 6.4 |
| Return on Equity (ttm) | 14.6 |
Fri, 28 Aug 2026
Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares - Stock Titan
Fri, 28 Aug 2026
Quest Diagnostics stock climbs on a $3.12 EPS beat - Ad-hoc-news.de
Tue, 25 Aug 2026
Quest Diagnostics Stock: Is Wall Street Bullish or Bearish? - Yahoo Finance
Tue, 25 Aug 2026
Quest Diagnostics brings a $29 biological-age report to the U.S.—no extra blood draw - Stock Titan
Mon, 24 Aug 2026
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference - PR Newswire
Mon, 24 Aug 2026
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |